Pheochromocytoma, Paraganglioma and Adrenocortical Carcinoma: Physiopathology and Diagnosis
- 1st Edition, Volume 133 - February 1, 2027
- Latest edition
- Editor: Marta Araujo Castro
- Language: English
Volume 133 provides a comprehensive and up-to-date overview of three of the most challenging endocrine neoplasms—pheochromocytoma, paraganglioma, and adrenocortical carci… Read more
Description
Description
Key features
Key features
- Comprehensive and multidisciplinary coverage: Integrates the latest advances in the molecular biology, genetics, pathophysiology, and diagnosis of pheochromocytoma, paraganglioma, and adrenocortical carcinoma, bridging basic science and clinical practice.
- State-of-the-art diagnostic approach: Provides an in-depth review of contemporary diagnostic tools, including biochemical testing, advanced imaging, histopathology, molecular profiling, and emerging biomarkers for accurate diagnosis, risk stratification, and personalized patient management.
- Authored by international experts: Features contributions from leading clinicians and researchers in adrenal endocrinology and oncology, offering evidence-based recommendations, practical insights, and perspectives on current challenges and future directions in the field.
Readership
Readership
Table of contents
Table of contents
Wilfredo Antonio Rivera and Alejandro Román
2. Cardiovascular disease in patients with pheochromocytoma: clinical presentation and diagnosis
Alessandro Parente and Kevin Verhoeff
3. Pheochromocytoma and paraganglioma in special situations: children, during pregnancy and cyanotic disease
Cristina Lamas Oliveira
4. Pheochromocytoma and paraganglioma: screening indications and biochemical diagnosis
María Bernarda Iriarte
5. Metastatic pheochromocytoma: risk factors, diagnosis and prognosis.
Sara Donato, Raquel Calheiros, Pedro Souteiro
6. Pheochromocytoma and paraganglioma: pathogenesis and molecular pathways
Carolina M. Perdomo, Lucía O`Connor y Sonsoles Guadalix
7..Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and hormonal evaluation
Joao Menino
8..Adrenocortical carcinoma: urine and steroid profiling
Felicia A. Hanzu
9. Molecular landscape and biomarkers in adrenocortical carcinoma
Teresa Alonso Gordoa and Javier Molina
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 133
- Published: February 1, 2027
- Language: English
About the editor
About the editor
MC
Marta Araujo Castro
Marta Araujo-Castro, MD, PhD, is a Consultant Endocrinologist in the Neuroendocrinology and Adrenal Unit of the Department of Endocrinology and Nutrition at Ramón y Cajal University Hospital, Madrid, Spain, and a researcher at the Ramón y Cajal Institute for Health Research (IRYCIS). She obtained her PhD from the Alcalá de Henares University, where she received the Extraordinary Doctorate Award for her research on personalized medicine in adrenal tumors using metabolomics.
Dr. Araujo-Castro completed her residency in Endocrinology and Nutrition at Hospital Universitario Puerta de Hierro Majadahonda and has developed extensive clinical and research expertise in adrenal and pituitary disorders, hereditary endocrine neoplasia, neuroendocrine tumors, and endocrine oncology. She coordinates the Adrenal and Pituitary Units at her institution and actively participates in multidisciplinary endocrine tumor and hereditary cancer boards. Her research focuses on translational endocrinology, particularly the identification of diagnostic, prognostic, and predictive biomarkers in adrenal and pituitary diseases, precision medicine, endocrine tumor genetics, and optimization of the management of patients with adrenal tumors, Cushing syndrome, pheochromocytoma/paraganglioma, and primary aldosteronism. She has led and participated in numerous national and international collaborative studies and is actively involved in several Spanish and European endocrine registries and research networks.
She is committed to advancing evidence-based endocrine practice through multidisciplinary collaboration, clinical research, education, and mentorship, with a particular focus on improving the diagnosis and personalized management of patients with hereditary endocrine tumor syndromes.